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Abstract
 
CD8
 
 
 
 T cell tolerance to self-proteins prevents autoimmunity but represents an obstacle to
generating T cell responses to tumor-associated antigens. We have made a T cell receptor
(TCR) transgenic mouse specific for a tumor antigen and crossed TCR-TG mice to transgenic
mice expressing the tumor antigen in hepatocytes (gag-TG). TCRxgag mice showed no signs
of autoimmunity despite persistence of high avidity transgenic CD8
 
 
 
 T cells in the periphery.
Peripheral CD8
 
 
 
 T cells expressed phenotypic markers consistent with antigen encounter in
vivo and had upregulated the antiapoptotic molecule Bcl-2. TCRxgag cells failed to proliferate
in response to antigen but demonstrated cytolytic activity and the ability to produce interferon
 
 
 
. This split tolerance was accompanied by inhibition of Ca
 
2
 
 
 
 flux, ERK1/2, and Jun kinase-
phosphorylation, and a block in both interleukin 2 production and response to exogenous in-
terleukin 2. The data suggest that proliferation and expression of specific effector functions
characteristic of reactive cells are not necessarily linked in CD8
 
 
 
 T cell tolerance.
Key words: CTL • hepatocyte • tumor immunology • autoimmunity • signaling
 
Introduction
 
The immune system has evolved to maximize the ability of
a host to respond to foreign antigens while preventing re-
activity to self-proteins. Negative selection during T cell
development in the thymus is not capable of deleting the
entire self-reactive repertoire, and potentially self-reactive
T cells can still be found in the periphery. As such T cells
represent a risk for autoimmune injury, multiple mecha-
nisms operate in the periphery to prevent effective trigger-
ing by self-antigen. By contrast, T cell–based immunother-
apy of cancer is often dependent on activation of these
incompletely deleted self-reactive T cells. Most of the de-
scribed human tumor antigens are nonmutated proteins
also expressed in normal tissues, and targeting such proteins
typically overexpressed in tumors provides a platform for
treating more than the rare subsets of tumors expressing
true tumor-specific antigens such as mutated oncogenes or
viral antigens in virally associated malignancies. Thus, tu-
mor immunity in many respects can be viewed as the flip-
side of autoimmunity, but in which the T cells reactive
with self-proteins mediate a beneficial antitumor effect
rather than induce disease. The development of effective T
cell therapies for cancer as well as improved methods to
prevent and treat autoimmune diseases will require better
understanding of how self-reactive T cells are maintained
in a tolerant state in the periphery and can be rescued.
Insights into both central (thymic) and peripheral T cell
tolerance have been obtained with the use of TCR trans-
genic mouse strains, which can provide large numbers of T
cells with specificity for a self-antigen. Studies in TCR
transgenic mice have demonstrated that a large proportion
of T cells reactive with self-antigens expressed in the thy-
mus are deleted, although some T cells escape and emigrate
to the periphery, in part by downregulation of receptor
molecules (1, 2). For antigen expressed in tissues other than
the thymus, reactive T cells may be deleted, or rendered
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nonresponsive in the periphery (3–5). Peripheral anergy
can result from downregulation of the TCR (6) or acces-
sory molecules such as CD8 (1), or from molecular disrup-
tion of signaling pathways (7, 8). A more passive tolerance
in the form of ignorance has also been described previ-
ously, in which naive T cells potentially reactive to a self-
antigen are not triggered by encounter with the normal tis-
sue, but can be activated to effector cells that do recognize
the normal tissue if stimulated by antigen in a more immu-
nogenic context (9).
Signaling and effector functions have been compared in
tolerant and nontolerant peripheral CD4
 
 
 
 T cells and, to a
more limited extent, CD8
 
 
 
 T cells. Anergic CD4
 
 
 
 or
CD8
 
 
 
 T cells produce none or only low levels of IL-2
compared with functional cells (10, 11, for a review, see
reference 12). Anergic CD4
 
 
 
 T cells also exhibit a block in
both ERK and Jun kinase (JNK)
 
*
 
 activation (8, 13), and
show a reduced Ca
 
2
 
 
 
 flux after antigen stimulation after in-
duction of anergy with either staphylococcal enterotoxin B
(14) or systemic injection of antigenic peptide (15). The
signaling defects in tolerant CD8
 
 
 
 T cells are less defined,
although Ca
 
2
 
 
 
 flux in tolerant CD8
 
 
 
 cells appears to be di-
minished (10, 16).
We have previously reported on the generation and ini-
tial characterization of a transgenic mouse strain expressing
FMuLVgag, the protein targeted by the dominant CTL re-
sponse to the FMuLV-transformed FBL tumor (17). The
strain was developed as a model for a potentially immuno-
genic tumor antigen expressed in normal tissue. The trans-
gene is under control of the albumin promoter and ex-
pressed, as demonstrated by RT-PCR, primarily in hepatic
tissue, with much lower levels in kidney and spleen, and
marginally detectable levels of mRNA in thymus. The
mice are tolerant to FMuLVgag with no detectable CD8
 
 
 
response after multiple in vivo immunizations, but func-
tional CD8
 
 
 
 T cells can be recovered from immunized
gag-TG mice after four weekly cycles of stimulation in
vitro with irradiated FBL and supplemental IL-2. These
rescued CTL, which had obviously escaped deletion, ex-
hibited similar avidity for FMuLVgag as CTL derived from
normal B6 mice. Primed FMuLVgag-specific CTL derived
from normal B6 mice retained function after transfer into
these transgenic mice and were capable of eradicating FBL
tumor in the transgenic host. However, these CTL caused
no autoimmune injury, despite sufficient expression of
FMuLVgag to tolerize the endogenous FBL-specific CTL
repertoire in vivo. These results, which suggest that strate-
gies to rescue such tolerant T cells could yield cells effective
and safe in tumor therapy, prompted the current study.
To study the defects in FMuLVgag tolerant T cells, we
have now generated a TCR transgenic mouse strain with a
receptor from a FMuLVgag-specific CD8
 
 
 
 CTL clone
(TCR-TG). Crossing these mice with the gag-TG strain
yields mice with a large population of T cells tolerant to a
potential tumor antigen. Our results demonstrate that pe-
 
ripheral tolerance is largely maintained by a block in the
ability of these self-reactive CTL to expand in response to
antigen stimulation, but does not interfere with induction
of effector functions such as cytolytic activity and expres-
sion of some effector cytokines.
 
Materials and Methods
 
Identification and Cloning of Full-Length TCR-
 
 
 
 and -
 
 
 
 Genes
Specific for FBL and FMuLVgag, and Generation of Transgenic
Mice.
 
CD8
 
 
 
 cytotoxic clones were generated by limiting dilu-
tion of spleen cells from a B6 mouse primed in vivo with 10
 
7
 
 ir-
radiated FBL tumor cells. The TCR-
 
 
 
 and -
 
 
 
 genes of a selected
clone specific for the CCLCLTVFL-epitope (18) were cloned as
follows: to determine TCR-
 
 
 
 and -
 
 
 
 gene usage, total RNA was
isolated using the signal transducer and activator of transcription
60 reagent (TEL-TEST “B” Inc.), and cDNA was synthesized
from 5 
 
 
 
g of total RNA using oligo(dT) primers and the Super-
script system (GIBCO BRL). To allow amplification and identi-
fication of TCR sequences in the absence of 5
 
 
 
 sequence infor-
mation, linker ligation, and subsequent PCR was performed as
described in reference 19. PCR amplification products were sub-
cloned and sequenced to determine TCR-
 
 
 
 and -
 
 
 
 chain usage.
Primers that spanned the corresponding full-length TCR-
 
 
 
 and -
 
 
 
sequences were then generated and used in PCR reactions to am-
plify full-length TCR-
 
 
 
 and -
 
 
 
 chains. Full-length chains were
cloned, sequenced, and subcloned using standard molecular
methodologies into the hCD2 transgenic expression vector that
directs transgene expression exclusively in T cells under control
of the human CD2 promoter and LCR (20, 21). For generation
of transgenic mice, the FMuLVgag-specific TCR-
 
 
 
 and -
 
 
 
 con-
structs were digested with KpnI and NotI to release the human
CD2 promoter/LCR/TCR-
 
 
 
 or -
 
 
 
 genes. The restriction di-
gests were purified, quantified, combined, and injected into B6
embryos using standard techniques. After initial PCR-screening
on tail DNA, potential founder mice were screened by flow cy-
tometry for expression of the transgenes, and a founder mouse
with both genes integrated on the same chromosome was se-
lected and bred in our facility.
The generation and initial characterization of the gag-TG
mice have been described previously (17). C57BL/6 (B6), B6
Thy1.1 congenic and Fas negative (lpr) mice were obtained from
The Jackson Laboratory. All mice were maintained under SPF
conditions in our animal facility, and our animal protocol was re-
viewed and approved by the Department of Comparative Medi-
cine’s Animal Care Committee.
 
Thymectomy.
 
5-wk-old mice were anaesthetized with a mix-
ture of Ketamine (0.13 mg/g body weight) and Xylazine (0.01
mg/g body weight). Thymi were removed by vacuum suction
through a 4–5-mm midline sternum incision (22).
 
Cell Lines, Media, Antibodies, and Peptides.
 
FBL-3, a Friend
virus-induced erythroleukemia of B6 (H-2
 
b
 
) origin, expresses
FMuLV-
 
env
 
- and -
 
gag
 
-encoded products and MHC class I mole-
cules, but does not express MHC class II molecules (22). E10 is a
FMuLV negative subline of the B6 EL-4 thymoma. The mapping
and the sequence (CCLCLTVFL) of the dominant H-2D
 
b
 
–
restricted FMuLVgag epitope in FBL in B6 mice has been de-
scribed previously (18), and the peptide was synthesized at the
University of Washington peptide facility. Unless otherwise
stated, all cell culture was performed in RPMI 1640 supple-
mented with antibiotics, 2-mercapthoethanol, and 10% FCS.
Fluorochrome-conjugated and biotinylated antibodies against
 
*
 
Abbreviations used in this paper: 
 
JNK, Jun kinase; TAA, tumor-associated
antigen. 
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CD4, CD8 V
 
 
 
3, V
 
 
 
12, Thy1.1, Thy1.2, CD44, TNF-
 
 
 
, IFN-
 
 
 
,
Bcl-2, and Ly6C were purchased from BD PharMingen, and
streptavidin TexasRed from Caltag Laboratories.
 
Analysis of Autoimmune Injury.
 
Livers from groups of 4–6-
wk-old TCR-TG and TCRxgag mice were fixed in formalde-
hyde, paraffin embedded, sectioned, and stained with H&E.
Coded specimens were analyzed for inflammation and lympho-
cyte infiltration by a reference pathologist (Phoenix Central
Laboratories).
 
Stimulation of Transgenic T Cells, Cytoxicity, and Proliferation As-
says.
 
For testing cytotoxic potential, 1.5 
 
 
 
 10
 
7
 
 splenocytes from
TCR-TG or TCRxgag mice were stimulated with 5 
 
 
 
 10
 
6
 
 irra-
diated (10,000R) FBL cells in T25 tissue culture flasks supple-
mented by 5 U/ml IL-2. After 3 d, the cultures were depleted of
CD4
 
 
 
 cells using Dynal magnetic beads (#114.05, Dynal Inc.)
according to the manufacturer’s protocol, and tested in standard
4 h 
 
51
 
[Cr]-release assays against labeled FBL, E10, or ConA blasts
alone, or E10 or ConA blasts pulsed with FMuLVgag peptide at
the indicated concentrations. ConA blast targets were generated
by first lysing erythrocytes from B6 and lpr spleen cells by os-
motic shock, and then incubating 5 
 
 
 
 10
 
6
 
 cells in a 24-well plate
for 48 h in the presence of 20 
 
 
 
g/ml concanavalin A (model no.
C0412; Sigma-Aldrich) before labeling with 
 
51
 
[Cr]. CTL lines
were generated in vitro by repetitive stimulation of 2 
 
 
 
 10
 
6
 
 cul-
tured cells with 2 
 
 
 
 10
 
6
 
 irradiated FBL in T25 flasks containing
5 
 
 
 
 10
 
6
 
 irradiated (2,000R) B6 splenocytes as feeders and 20 U/ml
IL-2 in a total volume of 10 ml. Lines were tested for cytolytic
activity 5 d after an in vitro stimulation.
For proliferative assays, spleen cells were compensated to
equilibrate for the number and percentage of potential responders
present. Splenocytes from TCR-TG mice contained 
 
 
 
2.5 to 4.5
times more CD8
 
 
 
 cells compared with splenocytes from TCRx-
gag mice, as well as 
 
 
 
2.5 to 4.5 times more TCR-
 
  
 
hi
 
cells in the
CD8
 
 
 
 population (see Fig. 1). Therefore, spleen cells were de-
pleted of CD4 cells, and 10
 
6
 
 cells from TCRxgag spleens or 10
 
5
 
cells from TCR mice together with 9 
 
 
 
 10
 
5
 
 B6 splenocytes were
added to individual wells (a 10-fold compensation) and stimu-
lated with 2 
 
 
 
 10
 
4
 
 irradiated FBL for 3 d followed by an 8 h
pulse with 
 
3
 
[H]-thymidine.
 
Cytokine ELISA.
 
10
 
5
 
 CD4-depleted splenocytes from TCR-
TG plus 9 
 
 
 
 10
 
5
 
 B6 splenocytes or 10
 
6
 
 CD4-depleted TCRxgag
were stimulated with 2 
 
 
 
 10
 
4
 
 irradiated FBL in a total volume of
200 
 
 
 
l in a 96-well round bottomed plate. After 72 h, 50 
 
 
 
l of
culture supernatant was harvested and murine IL-2 measured by
ELISA according to the manufacturer’s protocols (R&D Systems).
 
Intracellular Staining for Cytokine and Bcl-2 Expression.
 
10
 
7
 
splenocytes from TCR-TG and TCRxgag mice were stimulated
in a 12-well plate with 3 
 
 
 
 10
 
6
 
 irradiated FBL for 48 h. Golgi-
Plug (BD PharMingen) was added and 6 h later the cells were
washed, permeabilized using Cytofix/Cytoperm (BD PharMin-
gen), and stained for intracellular proteins according to the manu-
facturer’s protocol.
 
Analysis of p44/42 MAP Kinase and SAPK/JNK Phosphoryla-
tion.
 
Western blot analysis of p44/42 and SAPK/JNK was done
with kits (#9100 for P44/42 and #9250 for SAPK/JNK) from
New England Biolabs. Responder splenocytes were isolated from
TCR-TG and TCRxgag mice and depleted of CD4
 
 
 
 cells using
Dynabeads. B6 splenocytes were pulsed with 10 
 
 
 
g/ml FMuLV-
gag-peptide for 1 h, irradiated and washed for use as APC. The
responder cells were mixed in a 1:1 ratio with peptide-pulsed
APC, and then lysed in SDS-PAGE sample buffer at indicated
time-points. The samples were electrophoresed in SDS-PAGE,
and blotted using a semidry transfer system. After blocking for 3 h
 
in TBS, 0.1% Tween-20, 5% BSA at 25
 
 
 
C, the membranes were
incubated with primary Abs according to the manufacturer’s pro-
tocols (New England Biolabs). Specific binding was detected by
incubation with secondary HRP-conjugated Ab and ECL West-
ern blotting detection reagents (Amersham Pharmacia Biotech).
 
Measurement of Ca
 
2
 
 
 
 Flux by Flow Cytometry.
 
Intracellular
Ca
 
2
 
 
 
 was assessed as described previously (23). TCR-TG and
TCRxgag splenocytes expressing the Thy1.1 allomarker were
depleted of CD4 cells by Dynabeads, and labeled for 30 min with
(2 
 
 
 
g/ml) Indo-1 a.m. (model no. I1203; Molecular Probes).
During the labeling, cells were stained with Abs to Thy.1.1 and
CD4. After washing, the cells were analyzed by flow cytometry.
A base line was established and control or peptide treated B6
Thy1.2 APC were added. Intracellular Ca2  was measured in
cells gated as Thy1.1  and CD4  cells, and Ca2  was followed
over time. As a positive control, responder cells were treated with
2  g/ml ionomycin (Sigma-Aldrich).
Results
FACS® and Histological Analysis of TCR-TG and TCRx-
gag T Cells. Heterozygous TCR-TG mice expressing
the V 3/V 12 TCR specific for FMuLVgag in CD8  T
cells were crossed with homo- or heterozygous gag-TG
mice (17), and double-transgenic TCRxgag mice identi-
fied by flow cytometry for TCR expression and by PCR
for expression of FMuLVgag. Both TCR-TG and TCRx-
gag mice appeared healthy. Histologic analysis of livers
from TCRxgag showed no evidence of inflammation,
lymphocytic infiltration, or other hepatic abnormalities
(data not shown).
Thymocytes from 6-wk-old B6, TCR-TG, and TCRx-
gag mice were stained with Abs for CD4, CD8, V 3, and
V 12, and analyzed by flow cytometry (Fig. 1 A). More
thymocytes from TCR-TG mice were CD8 single posi-
tive than from B6, consistent with forced expression of a
MHC class I–restricted T cell receptor. However, in thy-
mocytes from TCRxgag mice, as compared with TCR-
TG mice, the proportion of single positive CD8 cells was
reduced from 20 to 6%, suggesting that the presence of
FMuLVgag in TCRxgag mice led to negative selection of
CD8  T cells during thymic development. In TCR-TG
mice,   90% of single CD8  cells expressed V 3 and
V 12, whereas in TCRxgag mice this proportion was re-
duced to 52%, These data suggest that, despite expression
of FMuLVgag from the liver-specific albumin promoter,
some maturing CD8   T cells in TCRxgag thymocytes
were encountering antigen in the thymus, leading to neg-
ative selection of a proportion of the gag-specific CTL
repertoire.
Splenocytes from TCR-TG mice had an expanded
fraction of CD8  T cells compared with normal B6 mice
with an inverted CD4:CD8 ratio, but the CD4:CD8 ratio
in TCRxgag mice was more similar to normal B6 mice
(Fig. 1 B). More than 90% of the CD8  population in
TCR-TG mice expressed both receptors compared with
 1% of the population in B6, indicating good peripheral
expression of the transgenes. However, the population of
CD8  T cells expressing both chains in TCRxgag mice1410 CTL Tolerance to a Tumor-associated Antigen
decreased to 22%, accompanied by a more heterogeneous
pattern of expression with proportionally fewer cells ex-
pressing high levels of both chains. This suggested that ex-
pression of FMuLVgag in TCRxgag mice caused both a
partial deletion of TCR-positive CD8  cells, as well as
downregulation of individual TCR chains on a fraction of
CD8  peripheral cells. Some variation of TCR expression
was observed in individual TCRxgag mice, containing
between 7- to 16-fold fewer CD8 /TCR-  hi spleno-
cytes than TCR-TG mice (n   10). The observed reduc-
tion in the proportion of CD8  cells expressing both re-
ceptor chains in the spleen as compared with the thymus
of TCRxgag mice suggested that some deletion of these
cells is also occurring in the periphery. Similar phenotypes
were detected in peripheral blood and lymph nodes (data
not shown).
Further evidence that T cells in TCRxgag mice had
been influenced by encountering antigen in the periphery
was provided by analysis of expression of Ly-6C and
CD44, which are both associated with an activation/mem-
ory phenotype (Fig. 1 C). More than 70% of CD8 
TCRxgag T cells were Ly-6C  and CD44Hi, whereas 4%
of CD8  TCR-TG cells were Ly-6C  and 29% were
CD44Hi.
TCR-TG and TCRxgag T Cells Can Both Be Induced to
Lyse Targets. The activated phenotype of CD8  TCRx-
gag cells suggested that the T cells had reacted to antigen in
vivo. Analysis of spleen cells from TCR-TG and TCRxgag
mice revealed that neither population could directly lyse
gag-expressing targets ex vivo, suggesting that these were
not primed effector cells. The potential for these cells to ac-
quire lytic function was assessed by stimulating for 3 d in
vitro with irradiated FBL cells and 15 U/ml IL-2, depleting
CD4  cells, and testing for lysis of FBL and peptide-pulsed
E10 targets (Fig. 2). After culture, effector cells from both
TCR-TG and TCRxgag spleens were capable of lysing the
FMuLVgag  FBL target. There was only a small difference
observed in the ability of TCR-TG and TCRxgag T cells
to lyse targets pulsed with titrating amounts of peptide,
with TCR-TG cells appearing slightly more lytic. How-
ever, this difference likely reflected the higher number of
CD8 /TCR-  hi cells contained in the initial responder
population from TCR-TG mice, as a two to fourfold com-
pensation for the derived E:T ratios would render the cy-
tolytic activities similar.
Figure 2. CTLs from TCR-TG and TCRxgag lyse gag-positive tar-
gets. 1.5   107 TCR-TG (white symbols) and TCRxgag (black symbols)
splenocytes were stimulated for 3 d with 5   106 irradiated FBL cells in
the presence of 5 U/ml IL-2. After 3 d, the cells were CD4 depleted and
tested in a standard 4 h 51[Cr]-release assay against FBL, E10, or E10 to-
gether with FMuLVgag peptide at indicated concentrations. E:T ratio of
50:1 and 10:1 are shown, However, the final CD8 /TCR-  hi ratio for
TCRxgag compared with TCR is overestimated  5–15 times based on
profiles in Fig. 1.
Figure 1. FACS® analysis of thymic and splenic T cells from B6,
TCR-TG, and TCRxgag. (A) Thymocytes were stained with CD4,
CD8, V 3, and V 12 and analyzed for CD4/CD8 expression (top) or
V 3/V 12 expression (bottom). V 3/V 12 plots are gated on CD4 /
CD8  thymocytes. (B) Splenocytes were stained with CD4 and CD8
(top) or V 3; V 12 and CD8 (bottom). V 3/V 12 plots are gated on
CD8  splenocytes. (C) For analysis of memory/activation phenotype of
splenocytes, cells were stained with CD8 and either Ly-6C (top) or
CD44 (bottom). All histograms are gated on CD8  splenocytes.1411 Öhlén et al.
Splenocytes from TCRxgag Mice Do Not Proliferate or Secrete
IL-2 but Do Produce IFN-  and TNF-  Effector Cytokines af-
ter Antigen Stimulation. Because the TCR complex in the
TCRxgag mice was capable of activating T cells to deliver
a lytic signal upon encounter with gag  target cells, we
next analyzed if these cells also proliferated in response to
antigen. To compensate for the lower number of CD8 /
TCR-  hi cells in spleens of TCRxgag mice, (Fig. 1), pro-
liferation and IL-2 production was assessed in stimulating
cultures containing 10-fold excess of TCRxgag responder
cells compared with TCR-TG cells (Materials and Meth-
ods). CD4-depleted TCR-TG and TCRxgag splenocytes
were stimulated for 3 d in vitro with FBL, and then pulsed
with 3[H]-thymidine. Although TCR-TG T cells prolifer-
ated in response to antigen, TCRxgag cells failed to re-
spond (Fig. 3 A). To determine if the lack of proliferation
resulted from an inability to produce IL-2, IL-2 production
after antigen stimulation was measured. CD4-depleted
splenocytes from TCR-TG and TCRxgag mice, compen-
sated 10-fold to equalize the number of potentially re-
sponding CD8  cells, were stimulated with FBL tumor
cells for 72 h in vitro, and culture supernatants collected
and analyzed by ELISA for the presence of IL-2 (Fig. 3 B).
TCR-TG T cells produced IL-2 in response to antigen
stimulation, whereas TCRxgag T cells did not. To deter-
mine if the failure to proliferate could be entirely explained
by this inability to produce IL-2, compensated numbers of
CD8  T cells were stimulated with antigen in the presence
of exogenous IL-2. The addition of 1–25 U/ml IL-2 in-
creased background proliferation, but did not result in de-
tectable antigen-specific proliferation by TCRxgag CD8 
T cells (Fig. 3 C), suggesting that the defect in proliferation
in response to antigen is more profound than only a defi-
ciency in endogenous IL-2 production. Similar prolifera-
tive assays were performed in the presence of 500–50 ng/
ml IL-4, 500– 50 ng/ml IL-7, or 500–50 ng/ml IL–15, al-
ternative cytokines with the potential to induce T cell pro-
liferation. Supplementation with these cytokines also failed
to augment the proliferative response of TCRxgag T cells
to antigen stimulation, with the stimulation index in all
conditions tested never equaling or exceeding 2.
Despite the block in proliferation in response to antigen
even in the presence of supplemental cytokines, the pres-
ence of lytic function after stimulation of TCRxgag CD8 
cells suggested that some effector functions were intact.
Therefore, we analyzed if TCRxgag T cells could produce
effector cytokines. IFN-  and TNF-  production was as-
sessed by intracellular staining for these cytokines after 6 h
of antigen stimulation. Both TCR-TG and TCRxgag T
cells produced IFN-  and TNF-  (Fig. 3 C). The lower
percentage of IFN- – and TNF- –producing CD8  cells
from TCRxgag mice compared with TCR-TG CD8 
splenocytes is consistent with the 2.5- to 4.5-fold lower
percentage of TCR-  hi cells in TCRxgag mice (Fig. 1).
Moreover, the amount of IFN-  and TNF-  being pro-
duced in responding cells appears to be relatively similar.
Thus, the only difference observed in IFN-  and TNF- 
production is a higher background in TCRxgag CD8 
cells, which may reflect consequences of a previous or re-
cent encounter with antigen in vivo.
TCRxgag CD8  T Cells Are Deficient in the Ras/MAPK
and SAPK/JNK Signaling Pathways and in Flux of Ca2  after
Antigen Stimulation. The ability of CD8  T cells from
TCRxgag mice to lyse targets and produce some IFN-  af-
Figure 3. TCRxgag mice do
not proliferate or produce IL-2
but retain IFN-  and TNF- 
production after antigen stimula-
tion. (A) To measure antigen-
specific proliferation, 0.1   106
CD4-depleted splenocytes from
TCR-TG plus 0.9   106 B6
splenocytes and 106 splenocytes
from TCRxgag mice were stim-
ulated with 2   104 irradiated
FBL for 3 d, and then pulsed
with 3[H]-thymidine for 8 h. For
analysis of IL-2 production (B),
0.1   106 CD4-depleted spleno-
cytes from TCR-TG plus 0.9  
106 B6 and 106 CD4-depleted
TCRxgag were stimulated with
2   104 irradiated FBL in a total
volume of 200  l in a 96-well
round bottomed plate. After 72 h,
50  l of culture supernatant was
harvested and murine IL-2 mea-
sured by ELISA. (C) The antigen-
specific response of TCRxgag in
the presence of IL-2 was measured
as in A, but with indicated amounts of IL-2 added to the wells. Intracellular staining for IFN-  and TNF-  production (D) was performed after stimulation of
TCR-TG or TCRxgag splenocytes with irradiated FBL. After 48 h, secretion of protein was prevented by addition of Golgi-Block reagent for 6 h and
cells permeabilized by Cytofix/Cytoperm. The cells were stained with anti-CD8 and anti–IFN-  or anti–TNF- . Plots were gated on CD8  cells.1412 CTL Tolerance to a Tumor-associated Antigen
ter antigen stimulation, but not proliferate or produce IL-2,
suggested interference with but not disruption of signals
through the TCR. Therefore, TCR-TG and TCRxgag
splenocytes were depleted of CD4  cells, stimulated in vitro
with peptide-pulsed APC, and phosphorylation of ERK1/
ERK2 and JNK as reflections of the Ras/MAPK and
SAPK/JNK pathways, respectively, was determined by
Western blot analysis. Nonstimulated CD8  T cells from
TCRxgag appeared to express slightly higher basal levels of
phosphorylated ERK and JNK than resting CD8  T cells
from TCR-TG mice, which would again be consistent with
a recent antigen encounter in vivo. T cells from TCRxgag
showed delayed kinetics and decreased total phosphorylation
of ERK1 and ERK2 after 45 min stimulation (Fig. 4 A), and
no evidence of Jun kinase phosphorylation (Fig. 4 B). Simi-
larly decreased ERK and JNK phosphorylation was seen in
TCRxgag CD8  T cells after stimulation in vitro for 72 h
(data not shown). Thus, the inhibition of activation of these
pathways could not be overcome by increasing the duration
of stimulation to the time when lytic activity was detected,
suggesting these signals need not be fully intact for transmis-
sion of a lytic signal in CD8  effector cells.
A more proximal signaling event, flux of Ca2  after
stimulation, was then examined: TCR-TG and TCRxgag
splenocytes congenic for the Thy1.1 allomarker were
loaded with Indo-1, labeled with antibodies against Thy1.1
and CD4, and analyzed by flow cytometry. After establish-
ing an Indo-1 baseline for the unstimulated gated Thy1.1 
CD4  cells, peptide-pulsed Thy1.2  B6 splenocytes were
added. TCR-TG T cells responded with a clear peak of in-
creased Ca2  to peptide-pulsed APC, but TCRxgag T cells
displayed only low oscillating levels of Ca2 . By contrast, T
cells from both TCR-TG and TCRxgag mice fluxed Ca2 
equivalently after exposure to ionomycin, suggesting that
the failure to flux Ca2  after antigen stimulation in TCRx-
gag T cells resulted from a defect in the quality of the signal
from the TCR.
TCRxgag CD8  CTL-mediated Lysis Is Independent on Fas
Expression on Target Cells. TCRxgag CD8  T cells effi-
ciently killed target cells in 4 h cytotoxicity assays despite
defects in signaling following target recognition. Such
acute cytotoxicity in short-term in vitro assays has been
shown to be mediated by either the Fas–FasL or perforin
pathway (24). To determine if TCRxgag T cells are medi-
Figure 4. TCRxgag T cells exhibit deficiencies in Ras/MAPK and SAPK/JNK as well as in flux of Ca2  after antigen stimulation. CD4-depleted sple-
nocytes from TCR-TG and TCRxgag mice were stimulated with irradiated B6 splenocytes pulsed with 10  g/ml gag-peptide. After stimulation, the
cells were lysed in SDS-PAGE sample buffer at indicated time points. The samples were run on a SDS-PAGE gel and blotted. Blots were probed using
primary Abs against phosphorylated forms of ERK1/2 (A) or JNK (B). Specific binding was detected by incubation with a secondary HRP-conjugated
Ab and ECL Western blotting detection reagents. For analysis of Ca2  flux (C), TCR-TG (black line) and TCRxgag (gray line) splenocytes expressing
the Thy1.1 allomarker were depleted of CD4 cells and labeled with Indo-1. During the loading, cells were stained with Abs against Thy.1.1 and CD4.
After washes, the cells were analyzed by flow cytometry in order to establish a base line. Control or peptide treated B6 Thy1.2 APC were added and after
gating on Thy1.1 /CD4  cells, the Ca2  was followed over time. As a positive control, responder cells were treated with 1  g/ml ionomycin.1413 Öhlén et al.
ating target lysis via Fas–FasL interactions, CD4-depleted
splenocytes from TCR-TG and TCRxgag mice were
stimulated for 3 d in vitro with irradiated FBL in the pres-
ence of IL-2, and tested for lysis of peptide pulsed ConA-
induced blast targets from B6 or Fas-negative lpr mice (Fig.
5). Both TCR-TG and TCRxgag T cells efficiently lysed
targets derived from lpr-mice, demonstrating that the lytic
activity was not dependent on Fas–FasL interactions. An al-
ternative mechanism for CTL-mediated lysis other than Fas
or perforin could result from the activity of TNF-  or
TNF- , although this generally is not detectable in short-
term cytolytic assays. To determine if the targets used in
our lytic assays were sensitive to TNF-mediated lysis, FBL
and E10 cells were cocultured with 5 ng/ml TNF-  or 100
pg/ml TNF- . Neither tumor was sensitive to these con-
centrations of TNF in either 4 or 24 h assays, whereas
L-cells which were not killed after 4 h were lysed at 24 h
(data not shown).
These results suggest that the observed lysis is mediated
via the perforin pathway. Analysis of freshly obtained TCR
as well as TCRxgag CD8  T cells revealed only low levels
of perforin expression by Western blot analysis. However,
after 3 d of in vitro stimulation with FBL, when cytolytic
activity is detectable, both TCR and TCRxgag CD8  cells
expressed high levels of perforin (data not shown), which
would be consistent with involvement of the perforin
pathway in target lysis.
Tolerant T Cells Persist in TCRxgag Mice after Thymec-
tomy. It was possible that the T cells with cytolytic activ-
ity detected in TCRxgag mice were cells that had not yet
undergone deletion or anergy. Thus, although such cells
may be destined for tolerization, the high output of naive T
cells from the thymus might permit recovery of very recent
emigrants. Therefore, the outflux of new T cells to the
periphery was eliminated by thymectomy of TCR-TG,
TCRxgag, and control B6 mice at 5–6 wk of age. 5 wk af-
ter surgery, peripheral T cells were analyzed by flow cy-
tometry for changes in the V 3 and V 12 positive popula-
tion (Fig. 6 A). The percent of CD8 /TCR-  hi cells and
TCR staining intensity was unchanged in both TCR-TG
and TCRxgag splenocytes 5 wk after thymectomy. After
stimulation of splenocytes for 3 d in vitro with irradiated
FBL, splenocytes from thymectomized mice exhibited sim-
ilar lytic activity as T cells from their euthymic littermates
(Fig. 6 B). Thus, the functional and morphological pheno-
type observed in the periphery of TCRxgag mice repre-
sents a stable population that is not being rapidly deleted
and replaced.
Tolerant TCRxgag T Cells Express Elevated Levels of
Bcl-2. As described above, tolerant CD8  T cells were capa-
ble of persisting in the periphery, and therefore must be ca-
pable of avoiding deletion despite expression of the toleriz-
ing antigens. Upregulation of antiapoptotic molecules in
CD8  T cells receiving the tolerizing signals might provide
a mechanism of avoiding deletion. Therefore, splenocytes
from TCR and TCRxgag were permeabilized and stained
with anti–Bcl-2 antibodies, and intracellular expression of
the protein analyzed by flow cytometry (Fig. 7). CD8 
TCRxgag cells expressed more Bcl-2 protein than CD8 
cells from TCR mice.
Recovery of Proliferating CD8  T Cells after Repeated In Vitro
Stimulation. The failure to detect a proliferative response
in CD8  T cells from TCRxgag mice could result from an
irreversible defect in signaling, or from an actively main-
tained tolerizing process. The latter possibility would suggest
that it might be possible to recover functional T cells with
high avidity. Therefore, we attempted to overcome the tol-
erant state and expand FMuLVgag reactive CD8  T cells by
removing the cells from the tolerogenic in vivo environ-
ment and repetitively stimulating the cells in vitro in the
presence of supplemental IL-2. Splenocytes from naive
TCR-TG and TCRxgag mice were stimulated weekly in
vitro with irradiated FBL and IL-2. Cell cultures from both
TCR-TG and TCRxgag splenocytes exhibited an initial
and similar contraction due to  80% cell death of the
CD8  population during the first weekly cycle. During the
second week and subsequent stimulation cycles, TCR-TG
CD8  cells responded with proliferation leading to accumu-
lation of CD8  T cells. TCRxgag T cells, however, did not
begin expanding the second week, and showed no change
in total cell number (data not shown). After 4 wk of culture,
TCRxgag cultures began expanding after stimulation in a
similar manner to cultures of TCR-TG T cells, and at this
time the CD8  splenocytes from cultured TCRxgag mice
Figure 5. CTL from TCRxgag lyse gag-positive targets
independently of Fas-expression. 1.5   107 TCR-TG
(black symbols) and TCRxgag (white symbols) splenocytes
were stimulated for 3 d with 5   106 irradiated FBL cells
in the presence of 5 U/ml IL-2. After 3 d, the cells were
CD4 depleted and tested in a standard 51[Cr]-release assay
using ConA-induced blasts from B6 or Fas-negative lpr
mice as targets. Target cells were labeled with 51[Cr] and
used either untreated or after pulse with 5  g/ml gag-pep-
tide. E:T ratios were 50:1, 10:1, and 2:1.1414 CTL Tolerance to a Tumor-associated Antigen
showed no difference in proliferative response to titrating
amounts of peptide compared with CD8  cells from TCR-
TG mice (Fig. 8) The results suggest that the defect(s) lead-
ing to proliferative inhibition were reversible, and that high
avidity clones were neither deleted nor permanently aner-
gized during tolerance induction.
Discussion
We have developed a transgenic model for the study of
tolerance to peripherally expressed candidate tumor-associ-
ated antigens (TAAs) based on a TCR transgenic mouse
expressing a FMuLVgag-specific, H-2Db-restricted TCR
and a transgenic mouse expressing FMuLVgag from the al-
bumin promoter. In double transgenic mice, the CD8  T
cells specific for the TAAs which is expressed mainly in the
liver, are maintained in a tolerant state. This tolerance re-
flects not only partial deletion during T cell development
in the thymus, but a peripheral population of antigen expe-
rienced cells that is functionally compromised.
The tolerant CD8  CTL retained the capacity to lyse
FMuLVgag  targets but had lost the ability to proliferate
and produce IL-2 in response to antigen stimulation. This
phenotype of “split tolerance” is similar to one described in
an in vitro model in which an initially IL-2 producing
CD8  CTL clone was tolerized by stimulation with fixed
APC, and became unable to proliferate in response to anti-
gen while maintaining lytic ability (11). In both our in
vivo and this in vitro model, production of the effector cy-
tokine IFN-  was less impaired than IL-2 production.
However, in another transgenic model of in vivo–induced
tolerance in CD8  cells in which the self-antigen is a ubiq-
uitously expressed male antigen, more global tolerance was
observed with not only a block in proliferation and cyto-
kine production, but also the absence of cytotoxicity (10).
The differences in these in vivo models may reflect the
magnitude as well as the ubiquitous nature of expression of
the tolerizing antigen HY, with the more restricted expres-
sion of FMuLVgag resulting in tolerance but a less severe
functional inhibition.
Figure 6. The tolerant cells in TCRxgag are a stable
population and not deleted in thymectomized animals.
5-wk-old TCR-TG and TCRxgag mice were anaesthetized
and their thymi removed. After 5 wk, splenocytes from
control and thymectomized mice were (A) stained with
CD8; V 3 and V 12, and after gating on CD8  cells, T
cell receptor expression was analyzed. For analysis of lysis
by thymectomized mice (B), 1.5   107 TCR-TG and
TCRxgag splenocytes from normal control (N) or adult-
thymectomized (ATx) mice were stimulated with 5   106
irradiated FBL cells in the presence of 5 U/ml IL-2. After
3 d, the cells were CD4 depleted and tested in a standard
51[Cr]-release assay against E10 or E10 pulsed with
FMuLVgag. E:T ratio was 50:1.1415 Öhlén et al.
We did not detect a defect in lytic function after antigen
stimulation of CD8  T cells from TCR-TG and TCRx-
gag mice, particularly after compensating for the propor-
tionally lower number of CD8 /TCR-  hi cells in
TCRxgag mice compared with TCR-TG mice. Despite
demonstrable cytolytic activity, signaling through the Ras/
MAPK and SAP/JNK pathways was abnormal. Cytolytic
function has been shown to be in part dependent on ERK
phosphorylation, but a subpopulation of CTL can lyse tar-
get cells via the perforin pathway independent of activation
of ERK (25). The role of JNK in CTL lysis has not been
extensively analyzed, but our results suggest that even a se-
vere defect in the ability to phosphorylate JNK is not detri-
mental for lytic function by CD8  T cells. This data is
consistent with a report showing that spontaneous and
ADCC-mediated lysis by NK cells is also independent of
JNK activation (26).
CTL can kill target cells in short term in vitro assays via
perforin release and by FasL-mediated ligation of Fas on
target cells (for a review, see reference 24). The effective
lysis of Fas-negative lpr targets by TCRxgag CTL show
that the lytic activity is not dependent on the Fas/FasL
pathway. Our results suggested that killing was mediated
via the perforin pathway. However, perforin-mediated lysis
has been reported to be Ca2  dependent (27, 28) and our
results showed freshly obtained TCRxgag T cells did not
efficiently flux Ca2 . Therefore, either this defect was suffi-
ciently restored after 3 d of in vitro stimulation to permit
activation of the cytolytic pathway, or the known sensi-
tivity for granular exocytosis to small changes in Ca2  is
below the level of detection in our assay (29). Other alter-
native mechanisms of killing, such as mediated by TNF-
release, are possible but in our view less likely because the
targets analyzed in this study are resistant to TNF, and also
because such mechanisms of lysis are generally not detect-
able in a 4 h cytolytic assay (24).
Several studies have suggested that maintenance of the
anergic state in self-reactive T cells requires continuous ex-
posure of the T cells to the tolerogen, and that the nonre-
sponsive state can be reversed after withdrawal of the anti-
gen (30–32). However, it is very difficult to mimic this
rescue condition in vitro and to keep T cells alive for pro-
longed periods of time in vitro in the absence of antigen
stimulation. Our results suggest an alternative strategy for
reversing anergy, in which the T cells are removed from
the tolerizing environment and repetitively stimulated in
vitro with the antigen presented by a functionally compe-
tent APC in the presence of IL-2. The recovery of reactive
CD8  cells is encouraging for developing T cell therapy
against TAAs in which tolerance may be an obstacle.
Figure 7. Tolerant TCRxgag cells CD8  express high
levels of Bcl-2. Fresh splenocytes from TCR and TCRxgag
were stained for CD8, and then permeabilized and stained
with antibodies for Bcl-2 or with isotype control anti-
bodies diluted in permeabilization buffer. After three
washes, cells were analyzed by flow cytometry for CD8
and Bcl-2 expression.
Figure 8. TCRxgag T cells that have been expanded in vitro by repet-
itive in vitro stimulations have similar avidity as T cells from TCR-TG
mice. 1.5   107 splenocytes from TCR-TG or TCRxgag mice were
stimulated with 5   106 irradiated FBL in T25 flasks in a total volume of
10 ml supplemented with 20 U/ml IL-2. The cultures were restimulated
every 7 d for 11 wk with 2   106 irradiated FBL, 5   106 irradiated B6
splenocytes as feeder cells and 20 U/ml IL-2. 8 d after last stimulation cul-
tures were tested in proliferation assay. 5   104 CD4-depleted cells from
TCR-TG (white symbols) and TCRxgag (black symbols) cultures were
stimulated with 5   105 irradiated B6 splenocytes pulsed with indicated
concentrations of peptide for 4 d in the presence of 5 U/ml IL-2, and
then pulsed with 3[H]-thymidine for 8 h.1416 CTL Tolerance to a Tumor-associated Antigen
Other transgenic in vivo models analyzing tolerance in-
duction have demonstrated that expression of an antigen in
peripheral tissues may lead to deletion of high avidity
CD8  cells from the host, with only low avidity T cells
persisting (33–35). In our model, CD8  cells with poten-
tially high avidity but a tolerant phenotype were shown to
persist in the host, suggesting a mechanism may be operat-
ing that provides protection from peripheral deletion. In-
creased expression of Bcl-2 has been shown to promote
survival and protect lymphocytes from apoptosis (36–38)
(for a review, see reference 39), and the tolerant CD8 
cells from TCRxgag mice were demonstrated to have up-
regulated Bcl-2. Thus, the encounter of CD8  T cells with
high affinity TCR with a tolerizing antigen in vivo can
lead to upregulation of antiapoptotic molecules despite the
development of anergy.
CD8  T cell tolerance can potentially result from nonre-
sponsiveness either at the afferent or at the efferent phase of
the immune response. Control of autoreactive T cells only
at the effector phase would be inefficient, as it would per-
mit in vivo expansion and accumulation of unusable toler-
ant T cells. Similarly, control of self-reactive T cells only by
prevention of proliferation seems undesirable, as retention
of lytic function could result in autoimmune injury. How-
ever, as long as tolerance keeps the frequency of autoreac-
tive T cells low by blockade of expansion, a small amount
of self-reactivity may be permissible to the host. Normally,
the frequency of CD8  CTL reactive with a particular self-
antigen in the absence of expansion is low due to clonal
diversity during T cell development. In our transgenic
model, however, the frequency of potentially self-reactive
CTL is very high, suggesting that there must be an alterna-
tive explanation for the lack of detectable autoimmune in-
jury. The TCRxgag T cells may not be directly lytic in
vivo, and only retain the capacity to become cytolytic if
exposed to antigen via a functionally competent APC
rather than normal tissue. This would be consistent with
the absence of spontaneous killing when TCRxgag spleno-
cytes were directly tested for cytolysis before 3 d of in vitro
stimulation with irradiated FBL. However, other protec-
tive mechanisms may also be operative in vivo. In a previ-
ous report describing the gag-TG mice, we reported that
gag-TG mice showed a remarkable resistance to CTL in-
duced liver injury after infusion of large numbers of FMuL-
Vgag-reactive effector CTL (17). The resistance of he-
patocytes to autoimmune damage may be a general
phenomenon for this tissue. In a transgenic model in which
tolerance was induced by expression of the alloantigen
H-2Kb from the albumin promoter, hepatocytes were also
resistant to H-2Kb–specific CTL-mediated autoimmune in-
jury (40). Additionally, potentially cytolytic CD8  T cells
are able to control viral replication in a hepatitis model,
presumably by release of inflammatory cytokines such as
IFN- , without a cytopathic effect on hepatocytes (41).
The means by which hepatocytes may be protected from
cytolysis in the above examples are unknown, but similar
mechanisms could be operative in our model as well as in
other normal tissues. In the induction phase of a T cell re-
sponse, inhibitory signals can be triggered through cross-
linking of CTLA-4 by B7.1 or B7.2 (for reviews, see refer-
ences 42 and 43). Recently two new molecules with ho-
mology to the B7 family, PD-L1 (44, 45), and PD-L2 (46),
were described and shown to inhibit T cell proliferation
and cytokine production upon binding to PD-1 on T cells.
In addition to being expressed in lymphoid tissues, PD-L1
is constitutively expressed in distinct parenchymal organs
such as murine heart and lung (45), while PD-L2 is ex-
pressed in mouse liver and lung (46). Both molecules might
thus be capable of inducing tissue specific tolerance in vivo
(44–46), and it is possible that these or some still unidenti-
fied molecules could be mediating inhibitory signals to
TCRxgag T cells in our model.
There are probably multiple mechanisms that can con-
tribute to the establishment and maintenance of T cell tol-
erance to self-proteins, and the difference in data derived
from different transgenic models may reflect this complex-
ity. Depending on the nature of the tissue and level of pro-
tein expression, some or all of these tolerance mechanisms
may be induced, resulting in either deletion or in function-
ally tolerant T cells with a range of potential phenotypes.
Thus, it may not be possible to design a universal strategy
for breaking tolerance to self-antigens for the generation of
tumor-reactive T cells, just as there are presumably multi-
ple distinct events that might lead to autoimmunity. Fur-
ther analysis of this and other models should continue to il-
luminate and ultimately resolve these issues.
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